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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 12, Revision 4 
(FGE.12Rev4): primary saturated or unsaturated alicyclic alcohols, 
aldehydes, acids and esters from chemical groups 1 and 7
1
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
This scientific opinion, published on 5 December 2013, replaces the earlier version published on 16 October 
2013*. 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate 12 flavouring substances in Flavouring Group Evaluation 12, Revision 4 
(FGE.12Rev4), including two additional substances, using the Procedure in Commission Regulation (EC) 
No 1565/2000. The present revision includes two additional flavouring substances: 12-beta-santalen-14-ol [FL-
no: 02.216] and 12-alpha-santalen-14-ol [FL-no: 02.217]. None of the substances was considered to have 
genotoxic potential. The substances were evaluated through a stepwise approach (the Procedure) that integrates 
information on structure–activity relationships, intake from current uses and the toxicological threshold of 
concern and available data on metabolism and toxicity. The Panel concluded that none of the 12 substances [FL-
nos: 02.134, 02.186, 02.216, 02.217, 05.157, 05.182, 05.183, 05.198, 08.135, 09.342, 09.670 and 09.829] gives 
rise to safety concerns at their levels of dietary intake, estimated on the basis of the maximised survey-derived 
daily intake approach. Besides the safety assessment of these flavouring substances, the specifications for the 
materials of commerce have also been considered. Specifications including complete purity criteria and identity 
for the materials of commerce have been provided for all 12 candidate substances. 
© European Food Safety Authority, 2013 
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1  On request from the European Commission, Question No EFSA-Q-2013-00549, adopted on 25 September 2013. 
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Poças, Fidel Toldra and Detlef Wölfle. Correspondence: cef@efsa.europa.eu  
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to deliver scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate 12 flavouring substances in the 
Flavouring Group Evaluation 12, Revision 4 (FGE.12Rev4), using the Procedure as referred to in 
Commission Regulation (EC) No 1565/2000. These 12 primary saturated or unsaturated alicyclic 
alcohol, aldehyde, acid and esters belong to chemical groups 1 and 7 of Annex I of Commission 
Regulation (EC) No 1565/2000. 
The present revision of FGE.12, FGE.12Rev4, includes the assessment of two additional flavouring 
substances, 12-beta-santalen-14-ol [FL-no: 02.216] and 12-alpha-santalen-14-ol [FL-no: 02.217], 
compared with FGE.12Rev3.  
Ten flavouring substances possess one or more chiral centres and additionally, owing to the presence 
of a double bond, three of these substances can exist as geometric isomers. For all 10 substances, the 
stereoisomeric composition has been specified sufficiently. 
The 12 flavouring substances are classified into structural class I according to the decision tree 
approach presented by Cramer et al. (1978). 
Four of the flavouring substances in the present group have been reported to occur in essential oils and 
in a few foods. 
In its evaluation, the Panel, as a default, used the maximised survey-derived daily intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach would, in a number of cases, grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified theoretical added maximum daily intake (mTAMDI) 
approach based on the normal use levels reported by Industry. In those cases where the mTAMDI 
approach indicated that the intake of a flavouring substance might exceed its threshold of concern, the 
Panel decided not to carry out a formal safety assessment using the Procedure. In these cases the Panel 
requires more precise data on use and use levels. 
According to the default MSDI approach, intakes of the 12 flavouring substances in this group in 
Europe range from 0.011 to 43 micrograms (µg) per capita per day, i.e. below the threshold of concern 
value for structural class I (1 800 µg/person/day) substances.  
The genotoxic potential of this group of flavouring substances cannot be fully assessed. However, the 
data available do not indicate a genotoxic potential and therefore do not preclude their evaluation via 
the Procedure. 
The flavouring substances are expected to be metabolised to innocuous products at the estimated 
levels of intake as flavouring substances. 
It is considered that on the basis of the default MSDI approach these 12 flavouring substances would 
not give rise to safety concerns at the estimated levels of intake arising from their use as flavouring 
substances.  
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When the estimated intakes were based on the mTAMDI they ranged from 2 to 5 000 µg/person/day 
for the 10 flavouring substances from structural class I for which use levels have been provided. For 
six of the substances the intakes were above the threshold of concern for structural class I of 
1 800 µg/person/day. Thus, for six flavouring substances considered in this Opinion, the intakes, 
estimated on the basis of the mTAMDI, exceed the relevant threshold for the structural class to which 
the flavouring substance has been assigned. For two substances [FL-no: 02.216 and 02.217], no use 
levels were provided. Therefore, for these eight substances [FL-nos: 02.134, 02.186, 02.216 and 
02.217, 08.135, 09.342, 09.670 and 09.829] more reliable exposure data are required. On the basis of 
such additional data, these flavouring substances should be reconsidered along the steps of the 
Procedure. Following this Procedure, additional toxicological data might become necessary. The four 
substances whose intake estimates as determined by the mTAMDI are below the threshold of concern 
for structural class I are also expected to be metabolised to innocuous products. 
In order to determine whether this evaluation could be applied to the material of commerce, it is 
necessary to consider the available specifications. Specifications including complete purity criteria and 
identity tests for the materials of commerce have been provided for each of the 12 flavouring 
substances. 
Thus, the Panel concluded that none of the 12 flavouring substances [FL-nos: 02.134, 02.186, 02.216, 
02.217, 05.157, 05.182, 05.183, 05.198, 08.135, 09.342, 09.670 and 09.829] would present any safety 
concern at the estimated levels of intake based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006. 
EFSA has evaluated 11 flavouring substances, which correspond to subgroup 1.1.2 of FGE.19, in its 
evaluation of the flavouring group 201 (FGE.201). The opinion was adopted on 25 September 2008. 
EFSA concluded that a genotoxic potential of the 11 α,β-unsaturated aldehydes and alcohol and 
related esters in the present FGE.201 could not be ruled out. 
Information on one representative material 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] 
has now been submitted by the European Flavour Association. This information is intended to cover 
also the re-evaluation of the following four substances from FGE.19 subgroup 2.1 (FGE.207): 
 12-beta-Santalen-14-ol [FL-no: 02.216] 
 12-alpha-Santalen-14-ol [FL-no: 02.217] 
 Santalyl acetate [FL-no: 09.034] 
 Santalyl phenylacetate [FL-no: 09.712]  
The Commission asks EFSA to evaluate this new information and depending on the outcome proceed 
to the full evaluation of the flavouring substances. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the following five substances: 12-beta-santalen-14-ol [FL-no: 02.216], 12-alpha-
santalen-14-ol [FL-no: 02.217], santalyl acetate [FL-no: 09.034], santalyl phenylacetate [FL-no: 
09.712] and 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931], in accordance with 
Commission Regulation (EC) No 1565/2000. 
                                                     
4 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5 EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1-
161. 
6 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
Flavouring Group Evaluation 12, Revision 4 
 
EFSA Journal 2013;11(10):3391 6 
INTERPRETATION OF THE TERMS OF REFERENCE  
The Flavour Industry had provided genotoxicity studies for the representative substance 2,6-dimethyl-
2,5,7-octatriene-1-ol acetate [FL-no: 09.931] and these data are considered by EFSA also to be 
representative for the substances [FL-no: 02.216 and 02.217]. Based on the new data, the Panel 
concluded in FGE.207 that 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] does not give 
rise to concern with respect to genotoxicity. This conclusion can also be applied to the substances 12-
beta-santalen-14-ol [FL-no: 02.216] and 12-alpha-santalen-14-ol [FL-no: 02.217], which will be 
evaluated through the Procedure in FGE.12Rev4. 
Flavouring Group Evaluation 12, Revision 4 
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ASSESSMENT 
1. History of the evaluation of the substances in the present Flavouring Group Evaluation  
The first version of the Flavouring Group Evaluation 12 (FGE.12) dealt with four primary saturated or 
unsaturated alicyclic alcohol, aldehyde, acid and esters. 
The first revision of FGE.12, FGE.12Rev1, included the assessment of three additional candidate 
substances [FL-nos: 02.134, 05.137 and 05.198]. Additional information on two substances [FL-nos: 
05.183 and 09.342] has been made available since FGE.12 was published. 
The second revision of FGE.12, FGE.12Rev2, includes the assessment of two additional candidate 
substances [FL-nos: 08.135 and 09.829]. No toxicity and/or metabolism data were provided for these 
substances. Furthermore, for four substances [FL-nos: 02.186, 05.157, 05.198 and 09.670] information 
from Industry (EFFA, 2010) on stereoisomeric composition and missing specifications, received after 
publication of the last revision, was included in Revision 2. 
The third revision of FGE.12, FGE.12Rev3, included the assessment of one additional candidate 
substance, 2,6,6-trimethylcyclohex-2-ene-1-carboxaldehyde [FL-no: 05.182]. No toxicity or 
metabolism data were provided for the substance. Furthermore, additional information on 
stereoisomeric composition for five substances [FL-nos: 02.186, 05.157, 05.182, 15.198 and 09.670], 
received after publication of Revision 2, was included in Revision 3. 
FGE Opinion adopted Link No of 
substances 
FGE.12 23 February 2005 http://www.efsa.europa.eu/en/scdocs/scdoc/208.htm  4 
FGE.12Rev1 28 August 2008 http://www.efsa.europa.eu/en/scdocs/scdoc/791.htm  7 
FGE.12Rev2 30 September 2010 http://www.efsa.europa.eu/en/efsajournal/doc/1846.pdf  9 
FGE.12Rev3 20 November 2012 http://www.efsa.europa.eu/en/efsajournal/pub/2993.htm  10 
FGE.12Rev4 25 September 2013  12 
 
The present Revision of FGE.12, FGE.12Rev4, includes the assessment of two additional flavouring 
substances, 12-beta-santalen-14-ol [FL-no: 02.216] and 12-alpha-santalen-14-ol [FL-no: 02.217]. 
These two substances have been considered with respect to genotoxicity in FGE.207 (EFSA CEF 
Panel, 2013) and the Panel concluded that the data available did rule out the concern for genotoxicity 
and thus concluded that the substances can be evaluated through the Procedure. 
No toxicity or metabolism data were provided for the two substances. A search in the open literature 
did not provide any further relevant data on toxicity or metabolism for these substances. 
2. Presentation of the substances in Flavouring Group Evaluation 12, Revision 4 
2.1. Description 
The present Flavouring Group Evaluation 12, Revision 4 (FGE.12Rev4), using the Procedure as 
referred to in Commission Regulation (EC) No 1565/2000 (EC, 2000) (the Procedure—shown in 
schematic form in Appendix A), deals with 12 candidate substances from chemical groups 1 and 7 of 
Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000).  
The 12 flavouring substances under consideration, as well as their chemical Register names, FLAVIS 
(FL) numbers, Chemical Abstract Service (CAS) numbers, Council of Europe (CoE) numbers and 
Flavor and Extract Manufacturers Association (FEMA) numbers, structure and specifications, are 
given in Table 1.  
Flavouring Group Evaluation 12, Revision 4 
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Out of the 12 substances, one is a primary saturated alicyclic acid [FL-no: 08.135], three are esters, of 
which two [FL-nos: 09.342 and 09.670] have a primary saturated or unsaturated alicyclic alcohol 
moiety and one [FL-nos: 09.829] is an ethyl ester of a saturated alicyclic carboxylic acid, two 
substances [FL-nos: 02.134 and 02.186] are primary alicyclic saturated alcohols, two substances [FL-
nos: 02.216 and 02.217] are primary alicyclic unsaturated alcohols and four are alicyclic unsaturated 
aldehydes [FL-nos: 05.157, 05.182, 05.183 and 05.198]. 
A summary of the safety evaluation is summarised in Table 5. 
The 12 flavouring substances (candidate substances) are structurally related to 18 flavouring 
substances (supporting substances), 16 of which were evaluated at the 59th meeting of the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) (data available in Appendix B) as 
―Alicyclic Primary Alcohols, Aldehydes, Acids, and Related Esters‖, one of which was evaluated, also 
at the 59th JECFA meeting, as a member of the group ―Phenethyl alcohol, aldehyde, acid and related 
acetals and esters‖ (JECFA, 2002a, 2003a) and one of which [FL-no: 09.931] was evaluated at the 
61st JECFA meeting as being in the group ―Aliphatic, branched-chain saturated and unsaturated 
alcohols, aldehydes, acids, and related esters‖ (JECFA, 2004a, b). The supporting substances, along 
with their structural formulas, FEMA, CoE and CAS Registry numbers, status as evaluated by the 
Scientific Committee on Food (SCF), JECFA and CoE, and their European maximised survey-derived 
daily intake (MSDI) values, are listed in Table 7. 
The hydrolysis products of the candidate esters are listed in Table 6. 
Flavouring Group Evaluation 12, Revision 4 
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Specification summary of the substances in the Flavouring Group Evaluation 12, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Physical form 
Molecular formula 
Molecular weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point (°C) (c) 
Melting point (°C) 
Identification test 
Assay minimum 
Refractive 
index (d) 
Specific 
gravity (e) 
Specification 
comments 
02.134 2-Cyclohexylethan-1-ol 
 
 
 
4442-79-9 
Liquid 
C8H16O 
128.21 
Slightly soluble 
Freely soluble 
222 
 
MS 
95 % 
1.463–1.469 
0.918–0.924 
 
02.186 Myrtanol 
 
 
 
514-99-8 
Solid 
C10H18O 
154.25 
Practically 
insoluble or 
insoluble 
Freely soluble 
116 (16 hPa) 
77 
MS 
95 % 
n.a. 
n.a. 
Mixture of four 
diastereoisomers 
(EFFA, 2010). Four 
diastereoisomers, 
20–30 % of each, 
with a higher 
likelihood of the 
trans forms (EFFA, 
2012a) 
02.216 12-beta-Santalen-14-ol 
 
3006 
74 
77-42-9 
Liquid 
C15H24O 
220.36 
Insoluble 
Soluble 
129 (5.3 hPa) 
 
MS 
95 % 
1.498-1.509 
0.965-0.975 
EU Register name to 
be changed to beta-
santalol and CAS 
Registry number to 
81893-42-7. Mixture 
of diastereoisomers 
(EFFA, 2013a) 
02.217 12-alpha-Santalen-14-ol 
 
3006 
74 
115-71-9 
Liquid 
C15H24O 
220.36 
Insoluble 
Soluble 
302 
 
MS 
95 % 
1.498–1.509 
0.965–0.975 
Register name to be 
changed to alpha-
santalol and CAS 
Registry number to 
73307-63-8. Mixture 
of diastereoisomers 
(EFFA, 2013a) 
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FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Physical form 
Molecular formula 
Molecular weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point (°C) (c) 
Melting point (°C) 
Identification test 
Assay minimum 
Refractive 
index (d) 
Specific 
gravity (e) 
Specification 
comments 
05.157 Isocyclocitral 
 
 
 
1335-66-6 
Liquid 
C10H16O 
152.23 
Practically 
insoluble or 
insoluble 
Freely soluble 
214 
–55 
MS 
95 % 
1.484–1.490 
0.885–0.891 
Mixture of two 
positional isomers 
(95 % sum of 
isomers, mainly 
2,4,6-trimethyl-
cyclohex-3-ene-1-
carbaldehyde) 
(EFFA, 2010). 
Mixture of eight 
diastereoisomers 
(approximately 
12.5 % each) 
(EFFA, 2012a) 
05.182 2,6,6-Trimethylcyclohex-2-ene-1-
carboxaldehyde 
 
3639 
10326 
432-24-6 
Liquid 
C10H16O 
152.23 
Insoluble 
Soluble 
62 (0.4 hPa) 
 
MS 
99 % 
1.476–1.483 
0.950–0.957 
Racemate (EFFA, 
2012a) 
05.183 4-(2,6,6-Trimethylcyclohexenyl)-
2-methylbutanal 
 
 
 
65405-84-7 
Liquid 
C14H24O 
210.36 
Practically 
insoluble or 
insoluble 
Freely soluble 
305 
 
MS 
95 % 
1.468–1.474 
0.924–0.930 
Racemate. CAS 
Registry number to 
be changed to 
73398-85-3. 
New CAS Registry 
number refers to the 
racemate 
05.198 alpha-Methyl ional 
 
 
 
58102-02-6 
Liquid 
C14H22O 
206.33 
Practically 
insoluble or 
insoluble 
Freely soluble 
90 (0.1 hPa) 
 
MS 
95 % 
1.485–1.491 
0.911–0.917 
Mixture of (Z)- and 
(E)-isomers (EFFA, 
2010). Name to be 
changed to 3-
butenal, 2-methyl-4-
(2,6,6-trimethyl-2-
cyclohexen-1-yl) 
(EFFA, 2010). E-
form (60–90 %); Z-
form (10–40 %). In 
each case racemate 
(EFFA, 2012a) 
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FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Physical form 
Molecular formula 
Molecular weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point (°C) (c) 
Melting point (°C) 
Identification test 
Assay minimum 
Refractive 
index (d) 
Specific 
gravity (e) 
Specification 
comments 
08.135 4-(2,2,3-
Trimethylcyclopentyl)butanoic 
acid 
 
4529 
 
957136-80-
0 
Liquid 
C12H22O2 
198 
Slightly soluble 
Partially soluble 
140–143 
 
NMR MS 
99 % 
1.461–1.467 
0.955–0.961 
Composition of 
mixture: 50–60 % 4-
((1S,3R)-2,2,3-
trimethylcyclopentyl
)butanoic acid, 32–
40 % 4-((1R,3S)-, 0–
6 % 4-((1S,3S)-, 0–
4 % 4-((1R,3R)-  
09.342 Cyclogeranyl acetate 
 
 
 
54993-30-5 
Liquid 
C12H20O2 
196.29 
Practically 
insoluble or 
insoluble 
Freely soluble  
98 (13 hPa) 
 
MS 
95 % 
1.464–1.470 
0.958–0.964 
Racemate. CAS 
Registry number to 
be changed to 
69842-11-1. 
New CAS Registry 
number refers to the 
racemate 
09.670 Myrtanyl acetate 
 
 
 
29021-36-1 
Liquid 
C12H20O2 
196.29 
Practically 
insoluble or 
insoluble 
Freely soluble 
106 (9 hPa) 
 
MS 
95 % 
1.470–1.476 
0.969–0.975 
Mixture of R,S-
enantiomers, i.e. the 
(+)- and (–)- (cis)- 
and (trans)-isomers, 
mixture of all 
diastereoisomers 
(EFFA, 2010). Four 
diastreoisomers 20–
30 % each, with a 
higher likelihood of 
the trans forms 
(EFFA, 2012a) 
09.829 Ethyl cyclohexyl acetate 
 
2348 
218 
5452-75-5 
Liquid 
C10H18O2 
170.25 
Practically 
insoluble or 
insoluble 
Freely soluble 
211 
 
NMR MS 
95 % 
1.442–1.450 
0.945–0.948 
 
(a) Solubility in water, if not otherwise stated. 
(b) Solubility in 95 % ethanol, if not otherwise stated. 
(c) At 1013.25 hPa, if not otherwise stated. 
(d) At 20 °C, if not otherwise stated. 
(e) At 25 °C, if not otherwise stated. 
n.a., not available; MS, mass spectrometry; NMR, nuclear magnetic resonance. 
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2.2. Stereoisomers 
It is recognised that the geometrical and optical isomers of substances may have different properties. 
Their flavour may be different and they may have different chemical properties, resulting in possible 
variability in their absorption, distribution, metabolism, elimination and toxicity. Thus, information 
must be provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number, etc.). 
Ten of the 12 flavouring substances possess one or more chiral centres and additionally, owing to the 
presence of a double bond, three of these substances [FL-nos: 02.216, 02.217 and 05.198] can exist as 
geometric isomers. The stereoisomeric composition has been specified for all 10 substances (see Table 
1). 
2.3. Natural occurrence in food 
Three of the 12 candidate substances, 2-cyclohexylethan-1-ol [FL-no: 02.134], myrtanol [FL-no: 
02.186] and myrtanyl acetate [FL-no: 09.670], have been reported to occur in essential oils. One 
substance, 2,6,6-trimethylcyclohex-2-ene-1-carboxaldehyde [FL-no: 05.182], has been reported to 
occur naturally in grape brandy and tomato (TNO, 2012). No quantitative data were reported. 
Eight of the substances (Table2) have not been reported to occur naturally in any food items according 
to TNO (2000, 2009, 2013). 
Table 2:  Candidate substances not reported to occur in food (TNO, 2000, 2009, 2013) 
FL-no Name 
02.216 12-beta-Santalen-14-ol 
02.217 12-alpha-Santalen-14-ol 
05.157 Isocyclocitral 
05.183 4-(2,6,6-Trimethylcyclohexenyl)-2-methylbutanal 
05.198 alpha-Methyl ional 
08.135 4-(2,2,3-Trimethylcyclopentyl)butanoic acid 
09.342 Cyclogeranyl acetate 
09.829 Ethyl cyclohexyl acetate 
 
3. Specifications 
Purity criteria for the 12 candidate substances have been provided by the Flavouring Industry (EFFA, 
2003, 2004a, 2013a; Flavour Industry, 2009). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), the information is adequate for all 12 candidate substances (see Section 2.2 and Table 1). 
4. Intake data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the MSDI by assuming that the production figure represents only 60 % of use in food owing 
to underreporting and that 10 % of the total EU population are consumers (SCF, 1999). 
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However, the Panel noted that, as a result of year-to-year variability in production volumes, 
uncertainties in the underreporting correction factor and uncertainties in the percentage of consumers, 
the reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that, in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of flavoured products at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the TAMDI approach, which calculates intakes on the basis of standard 
portions and upper use levels (SCF, 1995) for flavourable beverages and foods in general, with 
exceptional levels for particular foods. This method is regarded as providing a conservative estimate 
of the actual intake of most consumers because it is based on the assumption that the consumer 
regularly eats and drinks several food products containing the same flavouring substance at the upper 
use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g. it may 
underestimate the intake of consumers who are loyal to products flavoured at the maximum use levels 
reported) (EC, 2000). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004b). 
4.1. Estimated daily per capita intake (MSDI approach) 
The intake estimation is based on the MSDI approach, which involves the acquisition of data on the 
amounts used in food as flavourings (SCF, 1999). These data are derived from surveys on annual 
production volumes in Europe. These surveys were conducted in 1995 by the International 
Organization of the Flavor Industry (IOFI). Flavour manufacturers reported the total amount of each 
flavouring substance incorporated into food sold in the EU during the previous year (IOFI, 1995). The 
intake approach does not consider the possible natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population7 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
In the present Flavouring Group Evaluation (FGE.12Rev4), the total annual volume of production of 
the 12 candidate substances for use as flavouring substances in Europe has been reported to be 
approximately 370 kg (EFFA, 2003, 2004a, 2007, 2011; Flavour Industry, 2009). Of this amount, 
350 kg is accounted for by one of these flavouring substances, 4-(2,2,3-trimethylcyclopentyl)butanoic 
acid [FL-no: 08.135]. For the 18 supporting substances the total annual volume of production is 
approximately 380 kg (JECFA, 2003a; EFFA, 2013b). 
On the basis of the annual volumes of production reported for the 12 candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated (see Table 5).  
                                                     
7 In the EU this amounts to 375 million. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production 
data are available for the enlarged EU. 
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The estimated daily per capita intake of 4-(2,2,3-trimethylcyclopentyl)butanoic acid [FL-no: 08.135] 
from use as a flavouring substance is 43 µg. For each of the remaining substances the estimated daily 
per capita intake is less than 1 µg (see Table 5). 
4.2. Intake estimated on the basis of the modified TAMDI (mTAMDI) 
The method for calculation of mTAMDI values is based on the approach used by SCF up to 1995 
(SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For 10 candidate substances, information on food categories and normal and maximum use levels8,9,10 
was submitted by the Flavour Industry (EFFA, 2003, 2004a, 2007, 2012b; Flavour Industry, 2009). No 
information on use levels has been submitted for 12-beta-santalen-14-ol [FL-no: 02.216] and 12-
alpha-santalen-14-ol [FL-no: 02.217]. 
The 10 candidate substances are used in flavoured food products divided into the food categories, 
outlined in Annex III of Commission Regulation 1565/2000 (EC, 2000), as shown in Table 3. For the 
present calculation of mTAMDI, the reported normal use levels were used. If different use levels were 
reported for different food categories, the highest reported normal use level was used. 
Table 3:  Use of candidate substances in various food categories for 10 candidate substances for 
which data on use have been provided 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All except [FL-no: 
05.182] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except [FL-nos: 
05.182, 08.135] 
03.0 Edible ices, including sherbet and sorbet All except [FL-no: 
08.135] 
04.1 Processed fruits All except [FL-no: 
08.135] 
04.2 Processed vegetables (including mushrooms and fungi, roots and tubers, 
pulses and legumes), and nuts and seeds 
None 
05.0 Confectionery All 
06.0 Cereals and cereal products, including flours and starches from roots and 
tubers, pulses and legumes, excluding bakery wares 
All except [FL-nos: 
05.182, 08.135] 
07.0 Bakery wares All except [FL-no: 
08.135] 
08.0 Meat and meat products, including poultry and game All except [FL-nos: 
05.182, 08.135] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All except [FL-nos: 
05.182, 08.135] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey Only [FL-no: 
08.135] 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. All except [FL-nos: 
05.182, 08.135] 
                                                     
8  ―Normal use‖ is defined as the average of reported usages and ―maximum use‖ is defined as the 95th percentile of reported 
usages (EFFA, 2002). 
9  The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004b). 
10 The use levels from food category 5, ―Confectionery‖, have been inserted as default values for food category 14.2, 
―Alcoholic beverages‖ ,for substances for which no data have been given for food category 14.2 (EFFA, 2007). 
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Food 
category 
Description Flavourings used 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-nos: 
05.182, 08.135] 
14.1 Non-alcoholic (―soft‖) beverages, excluding dairy products All 
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic 
counterparts 
All except [FL-no: 
05.182] 
15.0 Ready-to-eat savouries All except [FL-nos: 
05.182, 08.135] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—foods that 
could not be placed in categories 1–15 
All except [FL-no: 
05.182] 
 
According to the Flavour Industry, the normal use levels for the candidate substances are in the range 
0.002–20 mg/kg food, and the maximum use levels are in the range 0.02–100 mg/kg (EFFA, 2003, 
2004a, 2012b; Flavour Industry, 2009).  
The mTAMDI values for the 10 candidate substances from structural class I for which data have been 
provided (see Section 7) range from 2 to 5 000 µg/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 7 and Appendix C. 
5. Absorption, distribution, metabolism and elimination 
All 12 candidate substances in this group evaluation contain a monocyclic, bicyclic or tricyclic 
alicyclic moiety with substituents containing a primary alcohol, aldehyde, carboxylic acid or ester 
function. The evaluation of the metabolism and other aspects of kinetics of the candidate substances in 
this Flavouring Group Evaluation depend entirely on information on structurally related substances 
(see Table 7 and Appendix D) and on general knowledge on biochemistry and biotransformation of 
xenobiotic substances. 
It is expected that the three esters in this group will be hydrolysed to yield their component alcohols 
and carboxylic acids. It is also anticipated that these hydrolysis products may be absorbed and that any 
remaining unhydrolysed flavouring esters, after absorption, will be hydrolysed in the liver. 
Gastrointestinal absorption can also be expected for the alcohols, carboxylic acids and the aldehydes 
in the present group. 
The metabolic fate of the three component alcohols, the four candidate alcohols and the four aldehydes 
in this flavouring group is not completely elucidated. It can be expected that oxidation of the hydroxyl 
group or aldehyde group will result in the formation of carboxylic acids which can be conjugated and 
excreted. Alternatively, the component or free alcohols in this group may be conjugated to glucuronide 
or sulphate without any further oxidation. Further, the cyclohexene derivatives may undergo allylic 
hydroxylation of the ring and then possible oxidation to keto groups or conjugation with glucuronic 
acid. These polar metabolites are expected to be excreted in the urine. Three substances [FL-nos: 
05.198, 02.216 and 02.217] have a double bond in the side-chain. This is not anticipated to alter the 
major metabolic pathways outlined above. 
Neither the chemical structures of the candidate substances in this group nor the metabolic data 
available suggest that reactive metabolites could be generated. Hence, it may be expected that the 
candidate substances in this flavouring group are absorbed and metabolised to innocuous products, 
which are excreted. 
For more detailed information, see Appendix D. 
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6. Application of the procedure for the safety evaluation of flavouring substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 7. 
For the safety evaluation of the 12 candidate substances from chemical groups 1 and 7, the Procedure 
as outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations of the 
substances are summarised in Table 5. 
Step 1 
All 12 candidate substances are assigned to structural class I according to the decision tree approach 
presented by Cramer et al. (1978). 
Step 2 
It is anticipated that the three esters in this group will be hydrolysed to yield their component alcohols 
and carboxylic acids, and that the component alcohols and carboxylic acids as well as the four 
candidate alcohols, the four aldehydes and the carboxylic acid will be metabolised to innocuous 
products at the estimated levels of intake and, accordingly, proceed via the A-side of the Procedure.  
Step A3 
The estimated European daily per capita intakes from use as flavouring substances of the 12 candidate 
substances, which have all been assigned to structural class I, range from 0.011 to 43 µg. These 
estimated intakes are below the threshold of concern of 1 800 µg/person/day for structural class I.  
Accordingly, the substances would not be expected to be of safety concern at their estimated levels of 
intake based on the MSDI approach. 
7. Comparison of the intake estimations based on the MSDI approach and the mTAMDI 
approach 
The MSDI ranges from 0.011 to 43 µg per capita per day. These figures are below the threshold of 
concern value for substances belonging to structural class I (1 800 µg/person/day). 
The estimated intakes of the 10 candidate substance in structural class I for which data have been 
provided, based on the mTAMDI, range from 2 to 5 000 µg/person/day. For four of the substances 
[FL-nos: 05.157, 05.182, 05.183 and 05.198], the mTAMDI is below the threshold of concern of 
1 800 µg/person/day. For six candidate substances [FL-nos: 02.134, 02.186, 08.135, 09.342, 09.670 
and 09.829], the mTAMDI exceeds the threshold of concern, and for two substances [FL-nos: 02.216 
and 02.217] no information on use levels has been provided. 
Thus, for eight substances [FL-nos: 02.134, 02.186, 02.216, 02.217, 08.135, 09.342, 09.670 and 
09.829], further information is required. This would include more reliable intake data and then, if 
required, additional toxicological data. 
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, see 
Table 4.  
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Table 4:  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
( g/person/ 
day) 
mTAMDI 
( g/person/ 
day) 
Structural 
class 
Threshold of 
concern 
(µg/person/ 
day) 
02.134 2-Cyclohexylethan-1-ol 0.011 3 900 Class I 1 800 
02.186 Myrtanol 0.37 3 900 Class I 1 800 
02.216 12-beta-Santalen-14-ol 0.085  Class I 1 800 
02.217 12-alpha-Santalen-14-ol 0.11  Class I 1 800 
05.157 Isocyclocitral 0.011 1 600 Class I 1 800 
05.182 2,6,6-Trimethylcyclohex-2-ene-
1-carboxaldehyde 
0.061 2.1 Class I 1 800 
05.183 4-(2,6,6-
Trimethylcyclohexenyl)-2-
methylbutanal 
0.012 1 600 Class I 1 800 
05.198 alpha-Methyl ional 0.011 1 600 Class I 1 800 
08.135 4-(2,2,3-
Trimethylcyclopentyl)butanoic 
acid 
43 5 000 Class I 1800 
09.342 Cyclogeranyl acetate 0.24 3 900 Class I 1 800 
09.670 Myrtanyl acetate 0.58 3 900 Class I 1 800 
09.829 Ethyl cyclohexyl acetate 0.61 3 900 Class I 1 800 
8. Considerations of combined intakes from use as flavouring substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in the event of combined exposure to 
structurally related flavourings, the pathways could be overloaded. Therefore, combined intake should 
be considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are based only on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003, 2004a, 2007; EFFA, 
2011; Flavour Industry, 2009), the combined estimated daily per capita intake as flavourings of the 12 
candidate flavouring substances assigned to structural class I is 45 µg, which does not exceed the 
threshold of concern for a compound belonging to structural class I of 1 800 µg/person/day.  
The 12 candidate substances are structurally related to 18 supporting substances evaluated by the 
JEFCA at its 59th meeting (JECFA, 2003a). The estimated combined intake (in Europe) is 
approximately 43 µg/person/day for the 18 supporting substances assigned to structural class I. The 
total estimated combined intake of candidate and supporting substances (in Europe) would be 
approximately 88 µg, which does not exceed the threshold of concern for structural class I 
(1 800 µg/person/day). 
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9. Toxicity 
9.1. Acute toxicity 
Studies were available for three of the 12 candidate substances and for nine supporting substances. 
The oral median lethal dose (LD50) in rats ranges from 1 to 5 270 mg/kg body weight (bw).  
The acute toxicity data are summarised in Appendix B (Table B1). 
9.2. Subacute, subchronic, chronic and carcinogenicity studies 
No studies were available for any of the 12 candidate substances.  
One study was available for the supporting substance 2,2,3-trimethylcyclopent-3-en-1-yl acetaldehyde 
[FL-no: 05.119]. This was a single dose level, 90-day gavage study in rats. The oral dose of 12 mg/kg 
bw/day did not induce adverse effects in this study. 
No carcinogenicity studies could be found either for the 12 candidate substances or for any of the 
18 supporting substances.  
Repeated-dose toxicity data are summarised in Appendix B (Table B2). 
9.3. Developmental/reproductive toxicity studies 
No studies on developmental or reproductive toxicity are available either for the 12 candidate 
substances or for the 18 supporting substances. 
9.4. Genotoxicity studies 
Data are available for the supporting substance 2,6-dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 
09.931], but no studies on genotoxicity are available for the 12 candidate substances.  
2,6-Dimethyl-2,5,7-octatriene-1-ol acetate [FL-no: 09.931] did not induce any biologically significant 
increases in bacterial mutation when evaluated in an Ames test in the presence and absence of S9 
metabolic activation. It did induce weak genotoxic effects in the in vitro micronucleus assay in an 
initial experiment in the presence of S9-mix at the highest concentration only. In a second experiment, 
although statistically significant increases were observed at the lowest and highest concentrations 
tested, these increases fell within the historical control range for the testing laboratory, and were not 
considered to be biologically important. The Panel therefore concluded that 2,6-dimethyl-2,5,7-
octatriene-1-ol acetate [FL-no: 09.931] does not give rise to concern with respect to genotoxicity.  
As 2,6-dimethyl-2,5,7-octatriene-1-ol acetate is considered representative of the two precursors for 
α,β-unsaturated alicyclic aldehydes [FL-nos: 02.216 and 02.217] from Subgroup 2.1 of FGE.19 
(FGE.207), the genotoxicity concern can also be ruled out for these two substances and, accordingly, 
they can also be evaluated through the Procedure. 
The genotoxic potential of the remaining flavouring substances cannot be fully assessed as the data are 
limited. However, this does not preclude evaluation of the candidate substances in the present group 
using the Procedure (SCF, 1999). 
The genotoxicity data are summarised in Appendix B (Table B3). 
CONCLUSIONS 
The present revision of FGE.12, FGE.12Rev4, includes the assessment of two additional candidate 
substances, 12-beta-santalen-14-ol [FL-no: 02.216] and 12-alpha-santalen-14-ol [FL-no: 02.217], 
compared with FGE.12Rev3. 
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Ten of the 12 flavouring substances possess one or more chiral centres and additionally, owing to the 
presence of a double bond, three of these substances can exist as geometric isomers. For all 10 
substances, the stereoisomeric composition has been specified sufficiently. 
All of the 12 candidate substances belong to structural class I according to the decision tree approach 
presented by Cramer et al. (1978).  
Four of the flavouring substances in the present group have been reported to occur naturally in 
essential oils and in a few foods. 
According to the default MSDI approach, estimated European daily per capita intakes of the 12 
candidate substances in this group resulting from their use as flavouring substances range from 
0.011 µg to 43 µg. These estimated intakes are below the threshold of concern of 1 800 µg/person/day 
for structural class I substances. 
On the basis of the reported annual production in Europe (MSDI approach), the combined intake of 
the 12 candidate substances belonging to structural class I would result in a total intake of 
45 µg/person/day. This value is below the threshold of concern for structural class I substances. The 
total combined intakes of the 18 supporting substances and the 12 candidate substances is 
approximately 86 µg/person/day, which is below the threshold of concern for structural class I 
(1 800 µg/person/day).  
The genotoxic potential of this group of flavouring substances cannot be fully assessed as the data are 
limited. However, this does not preclude evaluation of the flavouring substances in the present group 
using the Procedure. 
The 12 candidate substances are expected to be absorbed and metabolised to innocuous products, 
which will subsequently be excreted. The esters are expected to be hydrolysed to component alcohols 
and carboxylic acids, and the acids subsequently either oxidised completely or conjugated and 
excreted. The component alcohols, the candidate alcohols and the candidate aldehydes are expected to 
be oxidised to carboxylic acids, conjugated and excreted. The candidate substances, which are 
cyclohexene derivatives, may also undergo allylic ring hydroxylation and possible further oxidation or 
conjugation before excretion. Neither the chemical structures of the candidate substances in this group 
nor the metabolic data available suggest that reactive metabolites could be generated. 
No valid toxicity studies have been provided for any of the candidate substances and only one 
adequate subchronic study was available on a supporting substance. 
It is considered that, on the basis of the default MSDI approach, the 12 candidate substances would not 
give rise to safety concerns at the estimated levels of intake arising from their use as flavouring 
substances.  
When the estimated intakes were based on the mTAMDI they ranged from 2 to 5 000 µg/person/day 
for the 10 flavouring substances from structural class I for which use levels have been provided. The 
intakes were above the threshold of concern for structural class I, of 1 800 µg/person/day, for six 
flavouring substances [FL-nos: 02.134, 02.186, 08.135, 09.342, 09.670 and 09.829] and below the 
threshold for four flavouring substances [FL-nos: 05.157, 05.182, 05.183 and 05.198]. For two 
substances [FL-nos: 02.216 and 02.217] no use levels were submitted. Thus, for six of the 12 
flavouring substances considered in this Opinion, the intakes, estimated on the basis of the mTAMDI, 
exceed the relevant threshold for the structural class to which the flavouring substance has been 
assigned, and for two substances no use levels were submitted. Therefore, for eight substances more 
reliable exposure data are required. On the basis of such additional data, these flavouring substances 
should be reconsidered along the steps of the Procedure. Following this Procedure, additional 
toxicological data might become necessary. The four substances for which intake estimates according 
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to the mTAMDI approach are below the threshold of concern for structural class I substances are also 
expected to be metabolised to innocuous products. 
In order to determine whether the conclusion for the 12 candidate substances can be applied to the 
material of commerce, it is necessary to consider the available specifications. Specifications including 
complete purity criteria and identity for the materials of commerce have been provided for each of the 
12 flavouring substances.  
Thus, the Panel concluded that all 12 flavouring substances [FL-nos: 02.134, 02.186, 02.216, 02.217, 
05.157, 05.182, 05.183, 05.198, 08.135, 09.342, 09.670 and 09.829] would present no safety concern 
at the estimated levels of intake based on the MSDI approach. 
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SUMMARY OF SAFETY EVALUATION 
Table 5:  Summary of safety evaluation applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 
(a)
 
( g/person/
day) 
Class 
(b)
 
Evaluation procedure 
path 
(c)
 
Outcome 
regarding the 
named compound 
[
(d)
 or 
(e)
] 
Outcome on the 
material of 
commerce [
(f)
, 
(g)
 
or 
(h)
] 
Evaluation 
remarks 
02.134 2-Cyclohexylethan-1-ol 
 
0.011 Class I 
A3: Intake below threshold 
d f  
02.186 Myrtanol 
 
0.37 Class I 
A3: Intake below threshold 
d f  
02.216 12-beta-Santalen-14-ol 
 
0.085 Class I 
A3: Intake below threshold 
d f  
02.217 12-alpha-Santalen-14-ol 
 
0.11 Class I 
A3: Intake below threshold 
d f  
05.157 Isocyclocitral 
 
0.011 Class I 
A3: Intake below threshold 
d f  
05.182 2,6,6-Trimethylcyclohex-2-
ene-1-carboxaldehyde 
 
0.061 Class I 
A3: Intake below threshold 
d f  
05.183 4-(2,6,6-
Trimethylcyclohexenyl)-2-
methylbutanal 
 
0.012 Class I 
A3: Intake below threshold 
d f  
Flavouring Group Evaluation 12, Revision 4 
 
EFSA Journal 2013;11(10):3391 22 
FL-no EU Register name Structural formula MSDI 
(a)
 
( g/person/
day) 
Class 
(b)
 
Evaluation procedure 
path 
(c)
 
Outcome 
regarding the 
named compound 
[
(d)
 or 
(e)
] 
Outcome on the 
material of 
commerce [
(f)
, 
(g)
 
or 
(h)
] 
Evaluation 
remarks 
05.198 alpha-Methyl ional 
 
0.011 Class I 
A3: Intake below threshold 
d   
08.135 4-(2,2,3-
Trimethylcyclopentyl)butanoic 
acid 
 
43 Class I 
A3: Intake below threshold 
d f  
09.342 Cyclogeranyl acetate 
 
0.24 Class I 
A3: Intake below threshold 
d f  
09.670 Myrtanyl acetate 
 
0.58 Class I 
A3: Intake below threshold 
d f  
09.829 Ethyl cyclohexyl acetate 
 
0.61 Class I 
A3: Intake below threshold 
d f  
(a): EU MSDI: amount added to food as flavour in (kg/year)  109/(0.1  population in Europe (= 375  106)  0.6  365) = µg/person/day. 
(b): Thresholds of concern: class I = 1 800 µg/person/day, class II = 540 µg/person/day, class III = 90 µg/person/day. 
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
(d): Compound considered of no safety concern based on intake calculated by the MSDI approach. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or 
information on stereoisomerism. 
(h): No conclusion can be drawn owing to lack of information on the purity of the material of commerce. 
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EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 6:  Evaluation status of hydrolysis products of candidate esters 
FL-no EU Register 
name 
JECFA no 
Structural formula SCF status 
(a)
 
JECFA status 
(b)
 
CoE status 
(c)
 
EFSA status 
Structural class 
(d)
 
Procedure path (JECFA) 
(e)
 
Comments 
 Cyclogeraniol 
 
Not evaluated as flavouring substance  Not in EU Register 
02.078 Ethanol 
41  
Category 1 (SCF, 1995) 
 
 
No evaluation 
At the 46th JECFA meeting (JECFA, 
1997), the Committee concluded that 
ethanol posed no safety concern at its 
current level of intake when ethyl 
esters are used as flavouring agents 
02.186 Myrtanol 
 
 
 
 
FGE.12 
Class I 
A3: Intake below threshold 
 
08.002 Acetic acid 
81 
 
Category 1 (SCF, 1995) 
 
Category A (CoE, 1992) 
Class I 
A3, intake above threshold; A4, 
endogenous 
 
08.034 Cyclohexylacetic acid 
965 
 
 
 
Category B (CoE, 1992) 
Class I 
A3: Intake below threshold 
 
(a): Category 1, considered safe in use; category 2, temporarily considered safe in use; category 3, insufficient data to provide assurance of safety in use; category 4, not acceptable owing to 
evidence of toxicity. 
(b): No safety concern at estimated levels of intake. 
(c): Category A, flavouring substance, which may be used in foodstuffs; category B, flavouring substance which can be used provisionally in foodstuffs. 
(d): Threshold of concern: class I = 1 800 µg/person/day, class II = 540 µg/person/day, class III = 90 µg/person/day. 
(e): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
O H 
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SUPPORTING SUBSTANCES SUMMARY 
Table 7:  Supporting substances summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 
(a)
 
( g/person/ 
day) 
SCF status 
(b)
 
JECFA status 
(c) 
CoE status 
(d)
 
Comments 
02.114 2-(2,2,3-
Trimethylcyclopent-3-
enyl)ethan-1-ol 
 
3741 
 
1901-38-8 
970 
JECFA specification 
(JECFA, 2002b) 
0.012   
02.141 2-(6,6-
Dimethylbicyclo[3.1.1]hep
t-2-en-2-yl)ethan-1-ol 
 
3938 
 
128-50-7 
986 
JECFA specification 
(JECFA, 2002b) 
33   
05.098 p-Menth-1-en-9-al 
 
3178 
10347 
29548-14-9 
971 
JECFA specification 
(JECFA, 2002b) 
0.12   
05.112 2,6,6-Trimethylcyclohex-
1-en-1-acetaldehyde 
 
3474 
10338 
472-66-2 
978 
JECFA specification 
(JECFA, 2002b) 
0.24   
05.119 2,2,3-Trimethylcyclopent-
3-en-1-yl acetaldehyde 
 
3592 
10325 
4501-58-0 
967 
JECFA specification 
(JECFA, 2002b) 
5.0   
05.123 5-Isopropenyl-2-
methylcyclopentanecarbox
aldehyde 
 
3645 
 
55253-28-6 
968 
JECFA specification 
(JECFA, 2002b) 
0.012  JECFA evaluated 
cis-5-isopropenyl-
cis-
methylcyclopentan-
1-carboxaldehyde 
(CAS Registry 
number as in 
Register). CAS 
Registry number  in 
Register refers to the 
(Z,Z)-isomer 
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FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 
(a)
 
( g/person/ 
day) 
SCF status 
(b)
 
JECFA status 
(c) 
CoE status 
(d)
 
Comments 
08.034 Cyclohexylacetic acid 
 
2347 
34 
5292-21-7 
965 
JECFA specification 
(JECFA, 2002b) 
0.12  
 
Category B (CoE, 1992) 
 
08.060 Cyclohexanecarboxylic 
acid 
 
3531 
11911 
98-89-5 
961 
JECFA specification 
(JECFA, 2002b) 
0.061   
08.067 1,2,5,6-Tetrahydrocuminic 
acid 
 
3731 
 
71298-42-5 
976 
JECFA specification 
(JECFA, 2002b) 
0.012   
09.028 2-Cyclohexylethyl acetate 
 
2348 
218 
21722-83-8 
964 
JECFA specification 
(JECFA, 2002b) 
0.97  
 
Deleted (CoE, 1992) 
 
09.034 Santalyl acetate 
 
3007 
224 
1323-00-8 
985 
JECFA specification 
(JECFA, 2002b) 
0.1  
 
Category B (CoE, 1992) 
 
09.289 alpha-Campholene acetate 
 
3657 
 
36789-59-0 
969 
JECFA specification 
(JECFA, 2002b) 
0.061  JECFA evaluated 
campholene acetate 
(CAS Registry 
number as in 
Register) 
09.488 Ethyl 
cyclohexanepropionate 
 
2431 
2095 
10094-36-7 
966 
JECFA specification 
(JECFA, 2002b) 
0.12  
 
Deleted (CoE, 1992) 
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FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 
(a)
 
( g/person/ 
day) 
SCF status 
(b)
 
JECFA status 
(c) 
CoE status 
(d)
 
Comments 
09.534 Ethyl 
cyclohexanecarboxylate 
 
3544 
11916 
3289-28-9 
963 
JECFA specification 
(JECFA, 2002b) 
0.24   
09.536 Methyl 
cyclohexanecarboxylate 
 
3568 
11920 
4630-82-4 
962 
JECFA specification 
(JECFA, 2002b) 
0.073   
09.615 p-Menth-1-en-9-yl acetate 
 
3566 
10748 
28839-13-6 
972 
JECFA specification 
(JECFA, 2002b) 
0.85   
09.712 Santalyl phenylacetate 
 
3008 
239 
1323-75-7 
1022 
JECFA specification 
(JECFA, 2002b) 
0.029  
 
Category B (CoE, 1992) 
 
09.931 2,6-Dimethyl-2,5,7-
octatriene-1-ol acetate 
 
3886 
 
999999-91-4 
1226 
JECFA specification 
(JECFA, 2003b) 
1.2   
(a): EU MSDI: amount added to food as flavouring substance (kg/year)  10E9/(0.1  population in Europe (= 375  10E6)  0.6  365) = µg/person/day. 
(b): Category 1, considered safe in use; category 2, temporarily considered safe in use; category 3, insufficient data to provide assurance of safety in use; category 4, not acceptable owing to 
evidence of toxicity. 
(c): No safety concern at estimated levels of intake. 
(d): Category A, flavouring substance which may be used in foodstuffs; category B, flavouring substance which can be used provisionally in foodstuffs. 
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Appendix A.  Procedure for the safety evaluation 
The approach to a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the ―Procedure‖, is shown in schematic 
form in Figure A.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed 
on 2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995, 1996, 
1997, 1999a). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure–
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes, 1 800, 540 and 90 µg/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
 Can the flavourings be predicted to be metabolised to innocuous products11 (Step 2)?  
 Do their exposures exceed the threshold of concern for the structural class (Steps A3 and B3)? 
 Are the flavourings or their metabolites endogenous12 (Step A4)?  
 Does a NOAEL exist on the flavourings or on structurally related substances (Steps A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to ensure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warrant such actions. 
 
                                                     
11 ―Innocuous metabolic products‖: products that are known or readily predicted to be harmless to humans at the estimated intakes of 
the flavouring agent‖ (JECFA, 1997). 
12 ―Endogenous substances‖: Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated; 
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products? 
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety  
evaluation 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
 
 
  Substance would not be    
expected to be of safety concern 
Is the substance or are its metabolites endogenous? 
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4. 
 Yes  No 
 Yes 
 No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
 No 
Figure A.1: Procedure for safety evaluation of chemically defined flavouring substances 
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Appendix B.  Toxicity 
Oral acute toxicity data are available for three candidate substances of the present Flavouring Group Evaluation, and for nine supporting substances 
evaluated by the JECFA at the 59th meeting (JECFA, 2003a). The supporting substances are listed in brackets. 
Table B1: Acute toxicity 
Chemical name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Cyclohexanecarboxylic acid [08.060]) Rat  M, F Gavage 3 265 Moran et al., 1980 Study acceptable but number of dosage groups, and thus number of 
animals tested, has not been referred. 
(Methyl cyclohexanecarboxylate [09.536]) Rat  M, F  Gavage  3 881  Moran et al., 1980 Study acceptable but number of dosage groups has not been 
referred 
(Ethyl cyclohexanecarboxylate [09.534]) Rat  M, F  Gavage  3 962  Moran et al., 1980 Study acceptable but number of dosage groups has not been 
referred 
(Cyclohexaneethyl acetate [09.028]) Rat  NR  Oral  3 200  Wohl, 1974a Not adequate LD50 study 
 Rat  NR Oral 2 190 Moreno, 1978 The study is considered valid 
(2,2,3-Trimethylcyclopent-3-en-1-yl acetaldehyde 
[05.119]) 
Rat  NR  Oral  4 300  BIBRA, 1976 The LD50 value cited is deduced according to Litchfield and 
Wilcoxon (1949). Another LD50 value is also cited in the BIBRA 
study, 3 900 mg/kg, deduced according to Weill (1952) 
 Rat NR Oral 4 100 Moreno, 1978 Study acceptable. Substance name is given as ‗aldehyde 
campholenique‘ 
(Campholene acetate [09.289]) Rat  M, F  Gavage  M: 4 640–5 270  
F: 3 000  
Piccirillo et al., 1979 The study is considered valid 
(alpha-Campholenic alcohol [02.114]) Rat  NR Gavage  1 000–2 000  Levenstein, 1982 Study is inadequate for determination of LD50. Also, substance 
name is only given as code 
(1,2,5,6-Tetrahydrocuminic acid [08.067]) Rat  NR  Gavage  > 2 500  Levenstein, 1981 Study inadequate for derivation of LD50. Also, only code name 
given for substance 
4-(2,6,6-Trimethylcyclohexenyl)-2-methylbutanal 
[05.183] 
Rat  NR  Oral  > 5 000  Moreno, 1977a Study inadequate for derivation of LD50 Also, substance name 
given as ‗cetonal‘. It has not been possible to confirm that this is 
the same substance 
(10-Hydroxymethylene-2-pinene [02.141]) Rat NR Oral 890  Moreno, 1977b Study acceptable, but substance name given as Nopol. It has not 
been possible to confirm that this is the same substance 
2-Cyclohexylethan-1-ol [02.134] Rat NR Oral 0.94 Wohl, 1974b  
Isocyclocitral [05.157] Rat NR Oral 4.5 ml/kg bw Levenstein, 1973  
NR, not reported; M, male; F, female. 
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Subacute/subchronic/chronic/carcinogenic toxicity data are available for none of the candidate substances of the present Flavouring Group Evaluation but 
for one supporting substance evaluated by the JECFA at the 59th meeting (JECFA, 2003a). The supporting substance is listed in brackets. 
Table B.2. Subacute/subchronic/chronic/carcinogenicity studies 
Chemical Name [FL-
no] 
Species; sex 
No per group 
Route Dose level Duration 
(days) 
NOAEL (mg/kg bw/day) Reference Comments 
(2,2,3-
Trimethylcyclopent-3-en-
1-yl)acetaldehyde 
[05.119]) 
Rat; M, F 
8 
Gavage  12 mg/kg 
bw/day 
90 12 BIBRA, 1976 Single-dose study 
M, male; F, female; NOAEL, no observed effect level. 
B.1. Developmental and reproductive toxicity studies 
No developmental and reproductive toxicity data are available for the candidate substances of the present Flavouring Group Evaluation or for the supporting 
substances evaluated by the JECFA at the 59th meeting (JECFA, 2003a) or the 61st meeting (JECFA, 2004b).  
B.2. Genotoxicity (in vitro) 
In vitro mutagenicity/genotoxicity data are available for one structurally related candidate substance. No in vitro mutagenicity/genotoxicity data are 
available for the candidate substances of the present Flavouring Group Evaluation or for the supporting substances evaluated by the JECFA at the 59th 
meeting (JECFA, 2003a).  
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Table B.3. Summary of additional genotoxicity data for [FL-no: 09.931] of Subgroup 1.1.2 
Chemical name [FL-no] Test system in 
vitro  
Test 0bject  Concentrations of 
substance and test 
conditions  
Result  Reference  Comments  
2,6-Dimethyl-2,5,7-octatriene-
1-ol acetate [09.931] 
Reverse 
mutation 
Salmonella typhimurium 
TA98, TA100, TA1535, 
TA1537 and TA102 
5–1 500 μg/plate (a), (c) 
5–5 000 μg/plate (b), (c) 
Negative (a), (c) 
Equivocal (b), (c) 
King, 2000 Reliable without restriction. GLP study in compliance 
with OECD Guideline 471. A small increase in 
TA102 revertant numbers was seen at 15 and 50 
μg/plate in the presence of S9-mix, but not at higher 
concentrations 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
and TA102 
5–1 500 μg/plate (a), (c) 
5–5 000 μg/plate (b), (c) 
Negative (a), (c) 
Negative (b), (c) 
The small increase in TA102 revertant numbers seen 
in the first experiment at 15 and 50 μg/plate in the 
presence of S9-mix was not reproduced in the second 
experiment 
S. typhimurium TA102 5–1 500 μg/plate(b), (c) Negative The small increase in TA102 revertant numbers seen 
in the first experiment at 15 and 50 μg/plate in the 
presence of S9-mix was not reproduced in the third 
experiment 
Micronucleus 
assay 
Human peripheral blood 
lymphocytes (male donors) 
70–120 μg/mL (a), (d) 
120–225 μg/mL (b), (d) 
20–60 μg/mL( a), (e) 
119.2–290 μg/mL (b), (d) 
Weak positive +S9 
Retest within 
normal values 
Whitwell, 2012 Reliable without restriction. GLP study in compliance 
with OECD Guideline 487. Weak evidence of 
inducing micronuclei in the presence of S9-mix in a 
first experiment (increases only in one culture). A re-
test under the same conditions and using a higher top 
concentration resulted in MNBN frequencies within 
the historical negative control range at 95th 
percentile, but were statistically significant due to low 
vehicle control values 
(a):  Without S9-mix metabolic activation. 
(b):  With S9-mix metabolic activation. 
(c):  Plate incorporation method. 
(d):  Three-hour incubation with 21-hour recovery period. 
(e):  Twenty-four-hour incubation with no recovery period. 
GLP, good laboratory practice; OECD, Organisation for Economic Co-operation and Development; MNBN, micronucleated binucleate cell. 
 
B.3. Genotoxicity (in vivo) 
No in vivo mutagenicity/genotoxicity data are available for the candidate substances of the present Flavouring Group Evaluation or for the supporting 
substances evaluated by the JECFA at the 59th meeting (JECFA, 2003a) or the 61st meeting (JECFA, 2004b).  
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Appendix C.  Use levels/mTAMDI 
C1. Normal and maximum use levels 
For each of the 18 food categories (Table C.1) in which the candidate substances are used, the Flavour 
Industry reports a ―normal use level‖ and a ―maximum use level‖ (EC, 2000). According to the 
Industry, ―normal use‖ is defined as the average of reported usages and ―maximum use‖ is defined as 
the 95th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in different 
food categories have been extrapolated from figures derived from 12 model flavouring substances 
(EFFA, 2004b). 
Table C.1: Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000) 
Food 
category 
Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (including mushrooms and fungi, roots and tubers, pulses and legumes), and nuts 
and seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, including flours and starches from roots and tubers, pulses and legumes, 
excluding bakery wares 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic (―soft‖) beverages, excluding dairy products 
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—foods that could not be placed in categories 
01.0–15.0 
 
The ―normal and maximum use levels‖ are provided by Industry for 10 candidate substances in the 
present flavouring group (Table C.2). 
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Table C.2: Normal and maximum use levels (mg/kg) for the candidate substances in FGE.12Rev4 (EFFA, 2003, 2004a, 2007, 2012b; Flavour Industry, 2009) 
FL-no Food categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.134 7 
35 
5 
25 
10 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.186 7 
35 
5 
25 
10 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
05.157 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.182 – 
– 
– 
– 
0.01 
0,1 
0.005 
0.05 
– 
– 
0.005 
0.05 
– 
– 
0.006 
0.06 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
0.002 
0.02 
0 
0 
– 
– 
– 
– 
05.183 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
05.198 3 
15 
2 
10 
3 
15 
2 
10 
– 
– 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
– 
– 
– 
– 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
08.135 10 
30 
– 
– 
– 
– 
– 
– 
– 
– 
10 
40 
– 
– 
– 
– 
– 
– 
– 
– 
– 
– 
10 
40 
– 
– 
– 
– 
10 
30 
10 
40 
– 
– 
10 
40 
09.342 7 
35 
5 
25 
10 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.670 7 
35 
5 
25 
10 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.829 7 
35 
5 
25 
10 
50 
7 
35 
– 
– 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
– 
– 
– 
– 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
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C2. mTAMDI calculations 
The method for calculation of mTAMDI values is based on the approach used by SCF up to 1995 
(SCF, 1995). The assumption is that a person may consume the amount of flavourable foods and 
beverages listed in Table C.3. These consumption estimates are then multiplied by the reported use 
levels in the different food categories and summed up.  
Table C.3:  Estimated amount of flavourable foods, beverages, and exceptions assumed to be 
consumed per person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: candy, confectionery 27.0 
Exception b: condiments, seasonings 20.0 
Exception c: alcoholic beverages 20.0 
Exception d: soups, savouries 20.0 
Exception e: others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 (EC, 2000) and reported by the Flavour 
Industry in the following way (see Table C.4): 
 Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000) 
 Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 
16 (EC, 2000) 
 Exception a (SCF, 1995) corresponds to food categories 5 and 11 (EC, 2000) 
 Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000) 
 Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000) 
 Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000) 
 Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
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Table C.4: Distribution of the 18 food categories listed in Commission Regulation (EC) No 
1565/2000 (EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 
1565/2000 
Distribution of the seven SCF food 
categories 
Key Food category Food
 
Beverages
 
Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (including mushrooms and fungi, roots 
and tubers, pulses and legumes), and nuts and seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, including flours and starches from 
roots and tubers, pulses and legumes, excluding bakery wares 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and 
echinoderms  
Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic (―soft‖) beverages, excluding dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic 
counterparts 
  Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat)—
foods that could not be placed in categories 01.0–15.0 
Food   
 
The mTAMDI values (see Table C.5) are presented for 10 flavouring substances in the present 
flavouring group, for which Industry has provided use and use levels (EFFA, 2003, 2004a, 2007, 
2012b; Flavour Industry, 2009). The mTAMDI values are only given for the highest reported normal 
use levels. 
Table C.5: Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
( g/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
02.134 2-Cyclohexylethan-1-ol 3 900 Class I 1 800 
02.186 Myrtanol 3 900 Class I 1 800 
02.216 12-beta-Santalen-14-ol  Class I 1 800 
02.217 12-alpha-Santalen-14-ol  Class I 1 800 
05.157 Isocyclocitral 1 600 Class I 1 800 
05.182 2,6,6-Trimethylcyclohex-2-ene-1-
carboxaldehyde 
2.1 Class I 1 800 
05.183 4-(2,6,6-Trimethylcyclohexenyl)-2-
methylbutanal 
1 600 Class I 1 800 
05.198 alpha-Methyl ional 1 600 Class I 1 800 
08.135 4-(2,2,3-Trimethylcyclopentyl)butanoic 
acid 
5 000 Class I 1 800 
09.342 Cyclogeranyl acetate 3 900 Class I 1 800 
09.670 Myrtanyl acetate 3 900 Class I 1 800 
09.829 Ethyl cyclohexyl acetate 3 900 Class I 1 800 
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Appendix D.  Metabolism 
D1. Introduction 
The 12 candidate flavouring substances in this group evaluation are 2-cyclohexylethan-1-ol [FL-no: 
02.134], 12-beta-santalen-14-ol [FL-no: 02.216], 12-alpha-santalen-14-ol [FL-no: 02.217] myrtanol 
and its acetate [FL-nos: 02.186 and 09.670, respectively], four aldehydes, isocyclocitral [FL-no: 
05.157], 2,6,6-trimethylcyclohex-2-ene-1-carboxaldehyde [FL-no: 05.182], 4-(2,6,6-
trimethylcyclohexenyl)-2-methylbutanal [FL-no: 05.183] and alpha-methyl ional [FL-no: 05.198], one 
acid, 4-(2,2,3-trimethylcyclopentyl)butanoic acid [FL-no: 08.135], and ethyl cyclohexyl acetate [FL-
no: 09.829] as well as the acetate of cyclogeraniol [FL-no: 09.342]. For none of these candidate 
substances, were absorption, distribution, metabolism or elimination studies available. The assessment 
of the toxicokinetic properties of this group of substances relies therefore on general knowledge about 
biotransformation and data for representatives of a group of 18 structurally related (supporting) 
substances, 16 of which were evaluated during the 59th JECFA meeting as ―Alicyclic primary 
alcohols, aldehydes, acids, and related esters‖, one of which was evaluated, also at the 59th JECFA 
meeting, as a member of the group ―Phenethyl alcohol, aldehyde, acid and related acetals and esters‖ 
(JECFA, 2002a, 2003a) and one of which [FL-no: 09.931] was evaluated at the 61st JECFA meeting 
as being in the group ―Aliphatic, branched-chain saturated and unsaturated alcohols, aldehydes, acids, 
and related esters‖ (JECFA, 2004a, b). 
D2. Absorption, distribution, metabolism and elimination 
D2.1. Ester hydrolysis 
Two of the candidate substances in this Flavouring Group Evaluation are esters of alicyclic alcohols 
and acetic acid, cyclogeranyl acetate [FL-no: 09.342] and myrtanyl acetate [FL-no: 09.670], and one is 
an ester of alicyclic carboxylic acid and ethanol, ethyl cyclohexyl acetate [FL-no: 09.829], which can 
be expected to be subject to hydrolysis.  
Ester hydrolysis is catalysed by classes of enzymes known as carboxylesterases (Graffner-Nordberg et 
al., 1998), the most important of which are the B-esterases. Although these enzymes are present in 
most mammalian tissues, they predominate in the liver (Heymann, 1980; Graffner-Nordberg et al., 
1998). The substrate specificity of B-carboxylesterase isoenzymes has been correlated with the 
structure of the alcohol and acid components (Heymann, 1980). The aliphatic esters hydrolyse rapidly 
in liver homogenate, simulated pancreatic fluid, simulated gastric fluid and preparations of intestinal 
mucosa in vitro (Leegwater and van Straten, 1974a, b; Longland et al., 1977; Junge and Heymann, 
1979; Grundschober, 1977; Graffner-Nordberg et al., 1998). The results of in vitro studies indicate that 
the affinity of the esterases for their substrates increases as the length of the ester increases and that the 
rate of hydrolysis of the straight-chain esters is approximately 100 times higher than the rate of 
hydrolysis of the branched-chain esters (Arndt and Krisch, 1973; Butterworth et al., 1975; Junge and 
Heymann, 1979). 
Cyclohexanecarboxylate methyl ester and cyclohexanecarboxylate ethyl ester were incubated 
separately with 50 mL of simulated gastric fluid at 37 °C for six hours. The results showed 
approximately 20 % hydrolysis of each ester in the gastric fluid system. After a five-hour incubation in 
simulated intestinal fluid, approximately 40 % of cyclohexanecarboxylate methyl ester and 50 % 
cyclohexanecarboxylate ethyl ester were hydrolysed (Moran and Tyburcy, 1979). In an in vitro 
hydrolysis study, 100 % of cyclohexanepropionate ethyl ester was hydrolysed after two hours‘ 
incubation in 5 % pancreatin (Leegwater and van Straten, 1974a; Grundschober, 1977).  
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The in vitro hydrolysis of the structurally related ester p-1-(7)8-menthadien-2-yl acetate13 was 
investigated in rat liver homogenate. After incubation of this substance in homogenate at 37 °C for 15, 
30 and 60 minutes, complete (100 %) hydrolysis was observed after 60 minutes, with 92 % hydrolysis 
occurring within the first 15 minutes (Salzer, 1998).  
These data indicate that after oral exposure, the three candidate esters in this group of flavouring 
substances [FL-nos: 09.342, 09.670 and 09.829] will be hydrolysed either prior to absorption by 
enzymes in the gastrointestinal tract or after absorption by esterases in the liver to yield their 
component alcohols and carboxylic acids. The component acid (acetic acid) from two of these esters 
[FL-nos: 09.342 and 09.670] has been evaluated previously (e.g. FGE.01 or FGE.02) and the 
component ethanol from [FL-no: 09.829] (the JECFA had concluded that ethanol poses no safety 
concern at its current level of intake when ethyl esters are used as flavouring agents (JECFA, 1997)) 
will not be further discussed in this FGE. 
D2.2. Absorption, distribution and excretion 
For the candidate substances, data on absorption, distribution and excretion are not available. Some 
data are available on the sodium salt of the supporting substance cyclohexanecarboxylic acid [FL-no: 
08.060]13 and on the related substance perillyl alcohol.13  
D2.2.1. Cyclohexanecarboxylic acid
13 
Cyclohexanecarboxylate sodium salt containing a 14C-labelled ring was orally administered to male 
Wistar albino rats at a dose of 100 mg/kg bw. The results showed that > 98 % of the original dose was 
excreted as urinary metabolites within seven hours. Less than 1 % was excreted via the faeces or 
expired air (Brewster et al., 1977).  
Cyclohexanecarboxylic acid and 1-methyl-1-cyclohexanecarboxylate were studied in bile duct- and 
urinary tract-cannulated rats. Female Sprague–Dawley rats (four rats per compound) were 
administered via intravenous infusion a 0.52 mmol/kg bw bolus dose of cyclohexanecarboxylic acid 
(66 mg/kg bw) or 1-methyl-1-cyclohexanecarboxylate (73 mg/kg bw), followed by a 0.3-mL saline 
flush for each rat. Hardly any parent substance was excreted into urine or bile. Biliary excretion of 
base-labile (presumably glucuronide) conjugates accounted for approximately 5 and 59 %, and urinary 
excretion accounted for 12 and 25 % of the systemic elimination of cyclohexanecarboxylate and 1-
methyl-1-cyclohexanecarboxylate, respectively. The authors concluded that enterohepatic circulation 
of 1-methyl-1-cyclohexanecarboxylic acid, but not of cyclohexanecarboxylic acid itself, occurs (Liu et 
al., 1992). 
D2.2.2. Perillyl alcohol
13
 
The kinetics of p-mentha-1,8-dien-7-ol (i.e. perillyl alcohol) has been studied in rats, dogs and 
humans. This substance is most closely related to p-mentha-1,8(10)-dien-9-ol and its acetate [FL-nos: 
02.122 and 09.809, respectively] (Subgroup 2.1 of FGE.19 (EFSA, 2008)). 
Within four hours after a single dose of 1 000 mg perillyl alcohol/kg bw, administered to female 
Wistar–Furth rats via gavage, major plasma metabolites were identified as oxidised metabolites of 
                                                     
13 
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p-1-(7)8-menthadien-2-yl acetate cyclohexanecarboxylic acid perillyl alcohol  
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perillyl alcohol (perillic acid and dihydroperillic acid). No trace of perillyl alcohol was detected in the 
plasma at any time point, including 15 minutes post gavage (Haag and Gould, 1994). 
Two beagle dogs (male and female) administered 250 mg perillyl alcohol/kg bw by gavage exhibited 
peak plasma levels of oxidised metabolites of perillyl alcohol (i.e. perillic acid and dihydroperillic 
acid) at one and five hours post administration, respectively. Analysis of blood specimens collected 
before dosing and at 19 time points ranging from 10 minutes to 48 hours after dosing indicated the 
presence of the oxidised metabolites 10 minutes post administration. The parent substance, perillyl 
alcohol, was undetectable in the plasma (Phillips et al., 1995). 
Patients with various advanced malignancies were treated orally with doses of 800, 1 600 or 2 400 mg 
perillyl alcohol/m2/dose (equivalent to c. 32, 64 or 96 mg/kg bw/dose, assuming a body mass index of 
25 kg/m2). On the first day only a single dose was given, but thereafter the treatment was continued for 
four weeks, but on a three doses per day basis. Kinetic parameters were determined after the first and 
last dose. The parent drug was not detected in the plasma. Peak plasma levels (Cmax) of the two main 
metabolites of perillyl alcohol occurred at 1.5–3.5 hours (perillic acid) and 3–5 hours (dihydroperillic 
acid) post administration. Plasma elimination half-lives of the two metabolites studied were 1–6 hours 
and 2–3 hours, respectively. Repeated dosing did not affect Cmax values or the area under the curve 
(AUCs) values for these two metabolites, but there was a clear ―levelling of‖ of Cmax and AUC values 
when the dose of the metabolites increased from 1 600 to 2 400 mg/m2. Urinary metabolites were 
collected from the patients treated with the 2 400 mg/m2/dose up to 24 hours after the first dose or up 
to six hours after the last dose. In both cases ~ 1 % of the dose was collected as unchanged perillic 
alcohol. Approximately 10 % of the dose was recovered, less than 10 % of which was unchanged 
parent substance (Ripple et al., 1998). 
As part of a phase I dose-escalation trial, perillyl alcohol was administered per os (p.o.) at 800, 1 200 
or 1 600 mg/m2/dose (equivalent to c. 32, 48, or 64 mg/kg bw/dose, assuming a body mass index of 
25 kg/m
2
) to 16 patients with advanced refractory malignancies on a four times per day continuous 
basis for four weeks to characterise its kinetic profile, maximum tolerated dose, toxicity and 
antitumour activity. There appeared to be a dose-dependent increase in the plasma levels of the two 
main metabolites, perillic acid and dihydroperillic acid (see below). There was a trend towards 
decreasing metabolite levels on day 29 compared with days 1 and 2. Peak metabolite levels were seen 
one to three hours post administration and metabolite half-lives were about two hours. No indication 
of dose-related effects on the kinetics was obtained. Approximately 9 % of the total dose was 
recovered in the urine in the first 24 hours. Only ~ 0.1 % of the dose was recovered as parent 
substance (Ripple et al., 2000). 
From the above-mentioned studies it can be concluded that in humans, dogs and rats orally 
administered perillyl alcohol is rapidly absorbed and metabolised after ingestion. 
D2.3. Biotransformation 
D2.3.1. Cyclohexyl derivatives 
Metabolism studies conducted on representative flavouring agents indicate that these substances are 
metabolised primarily by oxidation of the primary alcohol or aldehyde function to yield the 
corresponding carboxylic acid or oxidation of the alkyl ring substituents to yield polyoxygenated polar 
metabolites that are readily excreted. 
The metabolic options available to alicyclic substances increase as the number and types of functional 
groups and ring substituents in the molecule increase. If a primary alcohol, aldehyde or carboxylic 
acid function is present on an alkyl side-chain of the ring, the substance may undergo beta-oxidation 
at the side-chain. For the present group of flavouring substances, this seems in particular important for 
[FL-no: 05.183 and 08.135], because these are the only ones with a side-chain which might be 
shortened by beta-oxidation. If the number of carbons present in the side-chain is odd, beta-oxidative 
Flavouring Group Evaluation 12, Revision 4 
 
EFSA Journal 2013;11(10):3391 44 
cleavage cannot continue beyond the point of side-chain attachment but the resulting carboxylic acids 
may be conjugated with glucuronic acid or glycine (Bernhard and Caflisch-Weill, 1945; Williams, 
1959; Brewster et al., 1977).  
D2.3.2. Terpenoid primary alcohols and aldehydes 
An indication of the metabolic fate of the monocyclic and bicyclic terpenoid aldehydes and alcohols 
(e.g. candidate substances myrtanol [FL-no: 02.186], isocyclocitral [FL-no: 05.157], 2,6,6-
trimethylcyclohex-2-ene-1-carboxaldehyde [FL-no: 05.182], cyclogeranyl acetate [FL-no: 09.342] and 
myrtanyl acetate [FL-no: 09.670] and supporting substances) can be obtained from the 
biotransformations of representative supporting substance aldehydes, p-mentha-1,8-dien-7-al (i.e. 
perillaldehyde) and 2-formyl-6,6-dimethylbicyclo[3.1.1]hept-2-ene (i.e. myrtenal), which are 
described below. In addition, for the metabolism of the flavouring substances isocyclocitral [FL-no: 
05.157], 2,6,6-trimethylcyclohex-2-ene-1-carboxaldehyde [FL-no: 05.182], 4-(2,6,6-
trimethylcyclohexenyl)-2-methylbutanal [FL-no: 05.183], alpha-methyl ional [FL-no: 05.198] and 
cyclogeranyl acetate [FL-no: 09.342], in which multiple and cycloalkene methyl side-chains occur, the 
metabolism of isophorone (3,5,5-trimethylcylohex-2-ene-1-one [FL-no: 07.126]),14 alpha-ionone [FL-
no: 07.007]14 and beta-ionone [FL-no: 07.008]14 might be used as an example. 
D2.3.3. Isophorone 
When isophorone11 was given to rabbits at an oral dose of 1 g/kg bw, glucuronic acid conjugates could 
be detected in the urine, and, after treatment of the urine with hydrochloric acid, the metabolite 5,5-
dimethyl-cyclohex-1-ene-3-one-1-carboxylic acid was found. This shows that for these substances 
oxidation of the methyl side-chain is a possible metabolic pathway, which, probably via alcohol and 
aldehyde intermediates, leads to formation of free or conjugated carboxylic acid end products (Truhaut 
et al., 1970). 
D2.3.4. Alpha- and beta-ionone
14
 
The candidate substances 2,6,6-trimethylcyclohex-2-ene-1-carboxaldehyde [FL-no: 05.182], alpha-
methyl ional [FL-no: 05.198] and cyclogeranyl acetate [FL-no: 09.342] are structurally related to 
alpha-ionone [FL-no: 07.007],11 and 4-(2,6,6-trimethylcyclohexenyl)-2-methylbutanal [FL-no: 05.183] 
is structurally related to beta-ionone [FL-no: 07.008].11 Available metabolic data on these two ionones 
indicate that they may undergo allylic ring hydroxylation and possible further oxidation to keto 
groups. These reactions result in the formation of polar metabolites, which are excreted in the urine 
unchanged or conjugated with glucuronic acid (JECFA, 1999b). It is anticipated that the four 
candidate substances [FL-nos: 05.182, 05.183, 05.198 and 09.342] may, at least to some extent, form 
similar polar metabolites and be excreted in the urine.  
D2.3.5. Perillyl alcohol and perillaldehyde 
The metabolism of perillyl alcohol, perillaldehyde and perillic acid was determined after intravenous 
injection in male Wistar rats and in exposed isolated rat hepatocytes. Although perillaldehyde can 
react spontaneously with glutathione (GSH), no indication of the formation of GSH conjugates was 
found either in vivo or in hepatocytes. After dosing with perillaldehyde, about 50 % of the doses were 
recovered as glucuronides in bile and urine. From perillic acid only the acyl glucuronide was 
generated, whereas perillyl alcohol and perillaldehyde formed both acyl and ether glucuronides. The 
results, together with those of studies in which alcohol dehydrogenase or aldehyde dehydrogenase was 
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inhibited, indicate that perillaldehyde is a major intermediary metabolite of perillyl alcohol in the rat in 
vivo and in rat hepatocytes in vitro (Boon et al., 2000). 
Six male rabbits were administered p-mentha-1,8-dien-7-al (perillaldehyde) orally at a dose level of 
2 000 mg per animal. Urine was collected for three consecutive days, pooled and treated with 
glucuronidase/aryl sulphatase. The neutral urinary fraction contained two metabolites accounting for 
7 % of the total amount of parent substance administered. These metabolites were identified as (-)-
perillyl alcohol and (–)-cis-shisool (i.e. para-menth-8-en-7-ol), representing 46 and 39 % of the 
neutral metabolites, respectively. The acidic fraction constituted 39 % of the administered amount of 
perillaldehyde and the two major metabolites in this fraction were perillic acid, which represented 
57 % of the acidic urinary metabolites and p-isopropylbenzoic acid (amount not specified). These 
results indicate that perillaldehyde was oxidised to p-mentha-1,8-dien-7-carboxylic acid (i.e. perillic 
acid). Aromatisation of the cyclohexene ring and reduction of the isopropenyl double bond converted 
perillic acid in part to p-isopropylbenzoic acid. To a lesser extent, p-mentha-1,8-dien-7-al was reduced 
to perillyl alcohol, which can be selectively hydrogenated to yield p-mentha-8-en-7-ol (see Figure 
D.1) (Ishida et al., 1989). Only a relatively small part of the administered dose was recovered. Other 
metabolites were not mentioned. 
 
O
OHO OHO
OH OH
Perillaldehyde
Perillic acid p-isopropenyl benzoic acid
major route
minor route
Perillyl alcohol p-menth-8-en-7-ol  
Figure D.1: Metabolism of perillaldehyde in rabbits 
Female Wistar–Furth rats were given a single oral dose of 100 mg perillyl alcohol/kg bw by gavage or 
were given a diet of 2 % perillyl alcohol for a period of 3, 5 or 10 weeks (nominally approximately 
1.5 g/kg bw/day). Perillic acid and dihydroperillic acid were detected as major plasma metabolites and 
perillic acid methyl ester and dihydroperillic acid methyl ester were identified as minor metabolites. 
The authors concluded that the methyl esters were artefacts formed during processing of urine. 
Unchanged perillyl alcohol was not detected after the gavage dose, not even at 15 minutes post 
gavage, nor after subchronic feeding. These results indicate that perillyl alcohol is rapidly absorbed 
from the gastrointestinal tract and metabolised. The presence of dihydroperillic acid indicates that the 
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endocyclic double bond was hydrogenated. After acute exposure, the perillic acid/dihydroperillic acid 
ratio amounted to > 10, while after 3–10 weeks of exposure via the diet this ratio had dropped to 2–3 
(Haag and Gould, 1994).  
An in vivo study conducted in male Wistar rats confirmed that the oxidation of perillyl alcohol to 
perillic acid involves perillaldehyde as an intermediate. Rats were administered intravenous perillyl 
alcohol, perillaldehyde or perillic acid at a dose of 80 mol/kg bw (approximately 12.2, 12.0 or 
13.3 mg/kg bw, respectively). Urine and bile were collected for two consecutive hours post 
administration. In all cases, the glucuronic acid conjugate of perillic acid was the predominant 
metabolite detected in the urine (10 % of the dose) and bile (46 % of the dose). The glucuronic acid 
conjugate of perillyl alcohol was also a major biliary metabolite following the intravenous 
administration of perillyl alcohol (5 %), while urinary excretion of this conjugate amounted to 1 % of 
the dose. Based on the results, the authors concluded that, within two hours, approximately 56 % of 
the original dose had been oxidised to perillic acid through perillaldehyde, and was eventually 
excreted as a glucuronic acid conjugate (Boon et al., 2000).  
Patients with various advanced malignancies were treated orally with one dose, followed by three 
daily doses, of 2 400 mg perillyl alcohol/m2 (equivalent to c. 96 mg/kg bw, assuming a body mass 
index of 25 kg/m2) on the following 29 days. Urinary metabolites were collected up to 24 hours after 
the first dose or up to 6 hours after the last dose. In both cases ~ 1 % of the dose was collected as 
unchanged perillic alcohol. Two metabolites were found, which constituted approximately 9 % of the 
dose,of which perillic acid accounted for ~ 90 % and dihydroperillic acid for ~ 10 %. Other 
metabolites were not monitored (Ripple et al., 1998). 
As part of a phase I dose-escalation trial, perillyl alcohol was administered p.o. at 1 200 or 
1 600 mg/m2/dose (equivalent to c. 48 or 64 mg/kg bw/dose, assuming a body mass index of 25 kg/m2) 
to 16 patients with advanced refractory malignancies on a four times per day continuous basis for four 
weeks. Approximately 9 % of the total dose was recovered in the urine in the first 24 hours on the first 
day of treatment and slightly more was recovered on day 15 or day 29 during 6 hours post dosing. At 
all time points, perillic acid accounted for approximately 80–85 % of recovered metabolites and 
dihydroperillic acid for 10–17 %. Only about 1 % of the dose was recovered as parent substance. 
Other metabolites were not monitored (Ripple et al., 2000). 
D2.3.6. Myrtenal 
Six male rabbits received an oral dose of 2 000 mg of 2-formyl-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene 
(= (–)-myrtenal) per animal. Myrtenol, dihydromyrtenol, myrtenic acid and perillic acid could be 
detected in the urine of these animals. Myrtenol and dihydromyrtenol together accounted for 99 % of 
the neutral metabolite fraction (5 % of the dose). Myrtenic acid represented 76 % of the acid 
metabolites detected in the urine, but the amount of perillic acid was not specified. The total acidic 
fraction of urinary metabolites constituted 24 % of the dose. These results indicate that myrtenal can 
be metabolised to the corresponding carboxylic acid (myrtenic acid). The presence of perillic acid 
indicates some cleavage of the strained bicyclic ring. To a lesser extent, the aldehyde can either be 
reduced to myrtenol, which may be conjugated with glucuronic acid and excreted, or may undergo 
hydrogenation of the double bond to yield dihydromyrtenol (myrtanol; see Figure D.2), which is one 
of the candidate substances [FL-no: 02.186] and has been shown to be the major neutral metabolite 
and is excreted unchanged in the urine (Ishida et al., 1989). Urine was collected for three days post 
dosing. Only a relatively small proportion of the administered dose was recovered. Other metabolites 
were not mentioned. 
Humans exposed to sawmill dust (Eriksson and Levin, 1990) excreted in the urine the glucuronic acid 
conjugate of myrtenol (2-hydroxymethyl-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene [FL-no: 02.091], the 
component alcohol in candidate flavouring substances [FL-no: 09.899 and 09.900]) (Subgroup 2.2 of 
FGE.19) (EFSA, 2008). The myrtenol was not detected in the sawdust (Eriksson and Levin, 1990), but 
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could have originated from side-chain oxidation of alpha-pinene (= 2,6,6-trimethyl-bicyclo[3.1.1]hept-
2-ene [FL-no: 01.004]) (FGE.78Rev1) (EFSA CEF Panel, 2011; Ishida et al., 1981). 
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Figure D.2: Metabolism of myrtenal in rabbits 
In summary, in mammals, monocyclic or bicyclic terpenoid primary alcohols (e.g. cyclogeraniol [from 
FL-no: 09.342] and myrtanol [FL-no: 02.186] (and from [FL-no: 09.670], and the structurally related 
substance perillyl alcohol) are generally oxidised to the corresponding carboxylic acid, conjugated 
with glucuronic acid and are excreted as urinary metabolites. The same is true for the monocyclic 
aldehyde (candidate substances isocyclocitral [FL-no: 05.157], 2,6,6-trimethylcyclohex-2-ene-1-
carboxaldehyde [FL-no: 05.182] and 4-(2,6,6-trimethylcyclohexenyl)-2-methylbutanal [FL-no: 
05.183]) and structurally related substances perillaldehyde and isophorone), which contain alkyl ring 
substituents. In a minor pathway, the aldehyde may be reduced to the alcohol and excreted as the 
glucuronide (Ishida et al., 1989; Haag and Gould, 1994). If an endocyclic double bond is present, 
reduction of this double bond may occur. 
D.3. Summary and conclusions 
The 12 candidate substances in this group evaluation contain a monocyclic, bicyclic or tricyclic 
terpenoid moiety, all with a primary oxygenated substituent. The evaluation of the metabolism and 
other aspects of kinetics of the candidate substances in this Flavouring Group Evaluation depends 
entirely on information on structurally related substances and on general knowledge of the 
biochemistry and biotransformation of xenobiotic substances. 
It can be expected that the esters in this group will be hydrolysed to yield their component alcohols 
and carboxylic acids. It can also be expected that these hydrolysis products may be absorbed, and that 
any remaining unhydrolysed flavouring substance after absorption will be hydrolysed in the liver. 
Gastrointestinal absorption can also be expected for the free alcohol and the free aldehyde in this 
group. 
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The metabolic fate of the component alcohols, the free candidate alcohols and the four aldehydes in 
this flavouring group is not completely elucidated. It can be expected that oxidation of the hydroxyl 
group or aldehyde group will result in the formation of carboxylic acids, which can be conjugated and 
excreted. Alternatively, the component or free alcohols in this group may be conjugated to glucuronide 
or sulphate without any further oxidation. Further, the cyclohexene derivatives may undergo allylic 
hydroxylation of the ring and then, perhaps, oxidation to keto groups or conjugation with glucuronic 
acid. These polar metabolites are expected to be excreted in the urine. 
Following absorption, the acids can be expected to be metabolised further via beta-oxidation (if 
applicable). Alternatively, they can be expected to be conjugated and excreted via the urine. 
Neither the chemical structures of the candidate substances in this group nor the metabolic data 
available suggest that reactive metabolites could be generated. Hence, it may be expected that the 
candidate substances in this flavouring group are absorbed and metabolised to innocuous products, 
which are excreted. 
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ABBREVIATIONS 
AUC area under the curve 
bw body weight 
CAS Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Cmax maximum plasma concentration 
CoE Council of Europe 
EFFA European Flavour and Fragrance Association 
EFSA European Food Safety Authority 
EU European Union 
FAO Food and Agriculture Organization of the United Nations  
FEMA Flavor and Extract Manufacturers Association 
FGE Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP Good Laboratory Practice 
GSH glutathione 
IR Infrared spectroscopy 
JECFA Joint FAO/WHO Expert Committee on Food Additives 
MNBN micronucleated binucleate cell 
MSDI maximised survey-derived daily intake 
mTAMDI modified theoretical added maximum daily intake 
NOAEL no observed adverse effect level 
NTP National Toxicology Program 
OECD Organization for Economic Co0operation and Development 
PCE Polychromatic erythrocyte 
p.o. per os 
SCF Scientific Committee on Food 
WHO World Health Organization 
